newsfilter
← Latest News
PR Newswire·

IDEAYA Biosciences Announces Successful US FDA Type C Meeting on Phase 2/3 Registrational Trial Designs to Support Potential Accelerated and Full Approval for IDE849, a Potential Best-in-Class DLL3 TOP1 ADC, in Neuroendocrine Carcinomas

  • IDEAYA Biosciences plans to initiate a single-arm extension cohort of approximately 90 refractory GEP-NEC patients by end-2026 to support potential accelerated approval, using ORR by BICR as the primary endpoint.
  • A randomized Phase 3 trial covering multiple refractory NEC subtypes, including GEP-NEC & LC-NEC, is targeted for initiation by end-2026 to support full approval, with OS as the primary endpoint.
  • IDEAYA intends to launch a randomized Phase 3 registrational trial for IDE849 in post-Imdelltra ES-SCLC by the end of 2026.
  • Clinical data from a global Phase 1/2 trial showed a 52.6% ORR (10/19), 7.0-month median PFS, & 82.4% 9-month OS rate in 2L+ NEC patients.
  • Safety data from the Phase 1/2 trial indicated Grade ≥3 TRAE rates of 5% (1/20) at 2.4 mg/kg & 22.2% (4/18) at 3.5 mg/kg expansion doses.
  • IDE849 is an investigational DLL3-targeting Topo-I-payload ADC currently dosed at 2.4 mg/kg or 3.5 mg/kg IV once every three weeks in the planned studies.
  • The company completed two Type C meetings with the U.S. FDA to align on registrational trial designs for refractory NEC & ES-SCLC.
  • IDE849 is being evaluated in a Phase 1/2 global trial across ES-SCLC & NEC, with observed Grade ≥3 ILD rates of 0.8% across 122 patients.
  • IDEAYA licensed global development & commercialization rights for IDE849 outside Greater China from Hengrui in December 2024.
Company
IDEAYA Biosciences, Inc.
Keywords
IDEAYA Biosciences, Inc.